Clinical Trials Logo

Post-Viral Fatigue Syndrome clinical trials

View clinical trials related to Post-Viral Fatigue Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT05430152 Recruiting - Clinical trials for Post-Viral Fatigue Syndrome

Low-dose Naltrexone for Post-COVID Fatigue Syndrome

Start date: January 15, 2024
Phase: Phase 2
Study type: Interventional

This study aims to determine if low-dose naltrexone (LDN) reduces fatigue, improves related symptoms, and reduces inflammatory markers in peripheral blood in cases with Post-COVID-19 Fatigue Syndrome (PCFS) from COVID-19 (i.e. confirmed SARS-CoV-2 case). LDN refers to naltrexone given in doses of 1-4.5 mg. Overall, studies have found that LDN is safe and well-tolerated. It may help to reduce pain and inflammation and improve well-being and immune function.The trial will be conducted by the Complex Chronic Diseases Program (CCDP) at BC Women's Hospital and will demonstrate whether LDN could benefit a large number of people with PCFS.

NCT ID: NCT05130736 Recruiting - Clinical trials for Post-Viral Fatigue Syndrome

Rehabilitation Robot in Patients With Post-Coronavirus Disease (COVID-19) Fatigue Syndrome

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to compare the effectiveness of two models of rehabilitation: - traditional neurological rehabilitation, and - neurological rehabilitation combined with a rehabilitation robot (Luna by EGZOTech). An additional goal is to test the qualitative diagnostic reference using the surface electromyogram of the Luna robot (certified as a Medical Device) for functional diagnostics based on standardized clinical tests.

NCT ID: NCT04705831 Recruiting - Covid19 Clinical Trials

Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Start date: December 30, 2020
Phase: Phase 4
Study type: Interventional

Randomized, Double Blind, Placebo Controlled, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection.